Blockchain Registration Transaction Record

Nutriband Founder Returns as CEO to Lead Fentanyl Patch Development

Nutriband founder Gareth Sheridan returns as CEO to lead AVERSA Fentanyl abuse-deterrent patch development toward 2026 NDA filing with $80-200M sales potential.

The development of abuse-deterrent opioid formulations represents a critical advancement in addressing the ongoing opioid crisis that has devastated communities worldwide. AVERSA Fentanyl's technology could significantly reduce the potential for misuse and accidental exposure to powerful opioids, potentially saving lives and reducing addiction rates. For patients who genuinely need potent pain management, this technology offers safer access to necessary medications while minimizing the risk of diversion and abuse. The successful development and approval of such technologies could set new standards for opioid safety and influence regulatory requirements across the pharmaceutical industry, ultimately benefiting public health and safety while providing legitimate pain patients with more secure treatment options.